ArticleESMO gastrointestinal oncology2026
Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA.
C Inagaki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.